Abstract
Cardiovascular disease (CVD) remains the leading cause of overall mortality in America for both men and women. A major risk factor for CVD is hyperlipidemia, a condition referring to elevated levels of at least one of five families of plasma lipoproteins-chylomicrons, very low-density lipoproteins, intermediate-density lipoproteins, low-density lipoproteins (LDL), and high-density lipoproteins (HDL).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Sources
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III)—NIH publication number 01-3670, May 2001.
LaRosa JC, et al. (2005) Intensive lipid lowering with Atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435.
Grundy SM (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel (III). Circulation 110:227.
Colhoun HM, et al. (2004) Collaborative Atorvastatin diabetes study (CARDS). Lancet 364:685–696.
Standards of Medical Care in Diabetes American Diabetes Association (2005) Diabetes Care 28:S4–S36.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Cohen, A., Skolnik, N.S. (2007). Hyperlipidemia. In: Skolnik, N.S., Schneider, D., Neill, R., Kuritzky, L. (eds) Essential Practice Guidelines in Primary Care. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-313-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-59745-313-4_2
Publisher Name: Humana Press
Print ISBN: 978-1-58829-508-8
Online ISBN: 978-1-59745-313-4
eBook Packages: MedicineMedicine (R0)